Empyrean Medical Systems Takes a Significant Step with FDA Submission of Vektra™ Therapy System

Empyrean Medical Systems Submits Vektra™ to FDA

Empyrean Medical Systems, Inc. declared a pivotal advancement in radiation oncology as it submitted a 510(k) premarket notification for its innovative Vektra™ system to the U.S. Food and Drug Administration (FDA). This groundbreaking submission signifies a crucial milestone in the company's strategic entry into clinical radiation therapy.

Vektra™ emerges as the world's premiere robotically assisted rapid beam-sculpting platform designed for brachytherapy as well as intraoperative radiation therapy (IORT). This cutting-edge technology facilitates the delivery of conformal doses targeting malignant tumors while concurrently minimizing exposure to surrounding healthy tissue and organs at risk (OARs). The introduction of Vektra™ empowers clinicians with new treatment avenues, ranging from invasive procedures to minimally invasive options, enhancing the care provided to cancer patients.

According to data from the International Atomic Energy Agency (IAEA), an estimated 15% of patients undergoing radiation oncology treatment will benefit from brachytherapy and IORT. Vektra™ is poised to disrupt the market with its precision, speed, and adaptability, capabilities that redefine standards in clinical practices.

Pavlina Frolik, Vice President of Sales and Marketing at Empyrean, expressed enthusiasm for the Vektra™ launch, stating, "We are excited to bring Vektra™ to market and make a meaningful impact on cancer patient care worldwide." She further emphasized the company’s commitment to collaborating with leading radiation oncology centers to foster clinical adoption, innovate treatment pathways, and translate this state-of-the-art technology into successful clinical outcomes for both practitioners and patients.

In a statement reflecting on the team's collaborative effort, Johnathan Vainer, Chief Technology Officer of Empyrean, expressed gratitude to the hardware and software research and development teams, quality assurance, regulatory support, and scientific partners that contributed to reaching this submission milestone. He highlighted Vektra™ as a significant evolution of the company's earlier Sculptura™ platform, which was cleared for use in 2019. The enhancements to Vektra™—such as automated source placement and increased treatment energy—were tailored based on feedback from partner centers of excellence, maximizing its precision and flexibility.

As Empyrean gears up for the next phase, which involves clinical deployment and scaling operations post-FDA clearance, the firm is steadfastly focused on changing the landscape of cancer treatment globally. Their proprietary technologies stem from an innovative approach crafted by researchers at MD Anderson Cancer Center, emphasizing patient safety, operational efficiency, and heightened treatment advantages with minimized side effects.

As the healthcare community anticipates the FDA's decision, the Vektra™ system is set to pave the way for the future of cancer care, ensuring that patients receive the most advanced and compassionate treatment available. Empyrean's mission remains steadfast: to revolutionize the way in which cancer treatments are delivered across the world, making significant contributions to improved patient experiences and outcomes.

For more information on Empyrean Medical Systems and their innovative technologies, visit www.empyreanmed.com.